Rituximab Compared With Mycophenolate Mofetil in Pemphigus Vulgaris Trial
Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data.
All articles by Diana Ernst, RPh
Persistent Diarrhea, Delirium, and Beefy Tongue: Is It Pellagra?
Severe micronutrient deficiency should be considered in the differential diagnosis in complex cases where a clear etiology is unknown.
First Treatment for Erythropoietic Protoporphyria Gets FDA Approval
The FDA has approved Scenesse for the treatment of patients with erythropoietic protoporphyria, a rare genetic metabolic disorder in which patients experience severe biochemical reactions following light exposure.
Aklief Cream Approved for Acne Vulgaris
The Food and Drug Administration (FDA) has approved Aklief Cream 0.005% (trifarotene; Galderma) for the topical treatment of acne vulgaris in patients 9 years of age and older.
Jynneos Gets FDA Approval for Smallpox, Monkeypox Prevention
The FDA has approved Jynneos (smallpox and monkeypox vaccine, live, non-replicating; Bavarian Nordic) for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk for these infections.
NDA for Plaque Psoriasis Treatment Wynzora Submitted for Review
The treatment was evaluated in a head-to-head phase 3 trial.
Teflaro Approved for Younger Patients to Treat Acute Bacterial Skin/Skin Structure Infections
The FDA has expanded the indication for Teflaro (ceftaroline fosamil; Allergan) to include treatment of acute bacterial skin and skin structure infections in pediatric patients.
Aczone Gel 7.5% Approved to Treat Acne in Younger Patients
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
DEA Proposes Less Opioid Production, More Marijuana for Research in 2020
Cuts are being proposed for 5 controlled substances based on estimates of diversion.
Ixekizumab vs Guselkumab: Efficacy Compared in Plaque Psoriasis Trial
A greater proportion of patients with moderate to severe plaque psoriasis achieved complete skin clearance with ixekizumab when compared with guselkumab, according to results from a phase 4 head-to-head study.
Next post in Psoriasis
